Carole S. Ben-Maimon, M.D.

Carole S. Ben-Maimon, M.D.

President and Chief Executive OfficeratLarimar Therapeutics· In proxies 2022–2025

Pay in FY2024-20% from the year before · Larimar Therapeutics stock -14.9% the same year

Carole S. Ben-Maimon, M.D. was paid $2.5M in FY2024 (Dec), down 20%. Larimar Therapeutics stock fell 14.9% that year.

Pay$100 in the stock at the end of FY21 → $36
Pay is from the Summary Compensation Table of each Larimar Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Larimar TherapeuticsPublic company · 4 yr
    • President and Chief Executive Officer2022 – Present · 4 yrStock in role -75%
  2. Teligent, IncPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?